Triglyceride Forum

30/09/2025

On Triglyceride Forum, catch up with fresh insights from Professors Gary Lewis and Gerald Watts in their new videos on the impact of weight loss injections on lipid levels and the challenges of designing essential clinical trials of novel medicines for people with raised triglyceride levels, some of whom may already be getting weight loss injections:

• GLP-1 agonists: Effects on plasma lipid profile?
🔗 https://www.triglycerideforum.org/expert-meetings/glp-1-agonists-effects-on-plasma-lipid-profile/

• Should we be lowering TG levels in the range between 150 mg/dL to 500 mg/dL and if so, how? Setting the scene
🔗 https://www.triglycerideforum.org/expert-meetings/should-we-be-lowering-tg-levels-in-the-range-between-150-and-500-mg-dl-and-if-so-how-setting-the-scene/

University of Toronto The University of Western Australia European Atherosclerosis Society (EAS) & Congress

25/09/2025

With growing medical interest in the protein, ANGPTL4, as a target for novel agents to reduce the risk of coronary artery disease and type 2 diabetes, Dr Sander Kersten and Dr Nicholas Marston discuss latest research and clinical trial data in their new video presentations on Triglyceride Forum. Watch the presentations:

• ANGPTL4: New insights into an “old” lipid regulatory protein 🔗 https://www.triglycerideforum.org/expert-meetings/angptl4-new-insights-into-an-old-lipid-regulatory-protein/

• ANGPTL4 inhibition: Phase 2a and ongoing trials 🔗 https://www.triglycerideforum.org/expert-meetings/angptl4-inhibition-phase-2a-and-ongoing-trials/

Wageningen University & Research European Atherosclerosis Society (EAS) & Congress Brigham and Women's Hospital/Massachusetts General Hospital

22/09/2025

A new medicine, olezarsen (Tryngolza), has received EU approval for the treatment of people with genetically confirmed familial chylomicronaemia syndrome ( ) – a condition that results in very high triglyceride levels in the blood and can lead to acute pancreatitis. Find out more about this and other new triglyceride-lowering treatments in development on Triglyceride Forum:

• Tryngolza (olezarsen) receives EU approval for FCS treatment > https://www.triglycerideforum.org/tryngolza-olezarsen-receives-eu-approval-for-fcs-treatment

• About clinical trials of TG-lowering agents > https://www.triglycerideforum.org/about-trials/

18/09/2025

How atherogenic are different types of lipid particle and where do remnant cholesterol particles fit into the complex puzzle of cardiovascular disease? In the first of a new series of videos on Triglyceride Forum, lipid experts, Dr Elias Björnson and Professor John Chapman, can bring you up to date with current thinking.

• Per particle atherogenicity: Remnants vs LDL vs Lp(a). Watch here … https://www.triglycerideforum.org/expert-meetings/per-particle-atherogenicity-remnants-vs-ldl-vs-lpa/

• Remnant lipoproteins: What do we know? Watch here … https://www.triglycerideforum.org/expert-meetings/remnant-lipoproteins-what-do-we-know/

European Society of Cardiology University of Gothenburg University Hospitals Pitié Salpêtrière

06/09/2025

Get up to date with new lipid research presented at this week’s European Society of Cardiology Congress including new ESC/EAS recommendations for lowering triglycerides, full results of the ESSENCE–TIMI 73b trial, and research linking ANGPTL3 to plaque calcification. Check out all our reports on Triglyceride Forum >> https://www.triglycerideforum.org/meeting-report/esc-congress-2025/


European Atherosclerosis Society (EAS) & Congress
European Society of Cardiology

05/09/2025

Good news for clinicians treating people with severe hypertriglyceridaemia this week. New results released from pivotal Phase 3 trials show that the apoC3 inhibitor, olezarsen, reduces acute pancreatitis by 85% and fasting triglyceride by up to 72% compared with placebo.

Find out more at … https://www.triglycerideforum.org/topline-core-and-core2-data-support-olezarsen-in-severe-hypertriglyceridaemia/

26/08/2025

Stay up to date with promising preclinical and early phase clinical trial results that support inhibition of ANGPTL4, a protein involved in lipid metabolism, for reducing triglyceride levels in the blood. We’ve brought the data together in our clinical trials update, journal news and congress report ..

https://www.triglycerideforum.org/trials/drugs/angptl4-inhibitors/

https://www.triglycerideforum.org/preclinical-data-support-mar001-safety-and-therapeutic-potential/

https://www.triglycerideforum.org/meeting-reports/angptl4-antibody-reduces-tg-and-remnant-cholesterol/

14/08/2025

How you process a fatty meal when you are young and healthy can provide useful clues to your future risk of cardiovascular disease and type 2 diabetes. Find out more about newly published research on Triglyceride Forum >> https://www.triglycerideforum.org/new-clues-to-link-between-postprandial-plasma-tg-and-cv-and-t2d-risk/

Biochemical and genomic results from a study of 21 healthy, non-obese individuals aged 18-40 years have shown that those with high post-prandial TG (HPTG) five hours after a high fat meal had significantly higher levels of plasma insulin and lipopolysaccharide-binding protein (LPB) than those with l...

07/08/2025

With fatty liver disease on the increase, new genetic data about identifying those with the condition who are at high risk of elevated triglycerides and subsequent cardiovascular disease are well timed. Read about the results from the Maastricht Study on Triglyceride Forum …
https://www.triglycerideforum.org/maastricht-study-shows-increased-htg-risk-with-steatotic-liver-disease/

Genetically predisposed individuals have a substantially higher risk of hypertriglyceridaemia when they also have steatotic liver disease, according to results from the Maastricht Study, a population-based, prospective cohort analysis.

22/07/2025

Looking for the latest trial data and insights on innovative therapeutics targeting triglycerides? Look no further.

We've comprehensive updates on the latest trials, as well as insights from experts and educational slides at

New insights into the biology of triglyceride (TG) metabolism underpin the development of novel therapies for managing hypertriglyceridaemia to reduce the

17/07/2025

⚠️ In case you missed it..

View our coverage from - held in Glasgow, Scotland - including a comprehensive review of trial data, at https://www.triglycerideforum.org/meeting-reports/

Meeting Reports Archive - Triglyceride Forum

14/07/2025

The Trigylceride Forum is a unique, independent, expert-led global initiative to address the rapidly evolving field of triglycerides and triglyceride-rich lipoproteins in cardiovascular disease and pancreatitis.

Find out more and join for free today, at

The Triglyceride Forum is a unique, independent, expert-led global initiative to address the rapidly evolving field of triglycerides and triglyceride-rich lipoproteins in cardiovascular disease and pancreatitis.